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Abstract We investigated whether dehydroepiandrosterone
(DHEA) or DHEA-sulfate (S) a¡ected the activities of nuclear
receptors, with special reference to constitutive androstane re-
ceptor L (CARL). Administration of DHEA or DHEA-S en-
hanced the DNA binding of hepatic nuclear extracts to respon-
sive elements for the retinoic acid receptor, the retinoic acid
receptor L 2 and the peroxisome proliferator activated receptor.
The bound complexes were shown to be the CARL-RXR het-
erodimer by antibody-supershift assays. The expression of a
target gene of CARL, Cyp2b10, was increased in liver by
DHEA or DHEA-S treatment, suggesting that DHEA or
DHEA-S actually activated CARL in vivo. It was suggested
that the metabolic conversion of DHEA, DHEA-S to CARL
ligands could occur in vivo and the metabolites could regulate
the expression of CARL target gene expression. Our results
provide new insights into the in vivo relationship between
DHEA/DHEA-S and CARL activation.
. 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Dehydroepiandrosterone (DHEA) and DHEA sulfate
(DHEA-S) are adrenal androgens and DHEA-S is the most
abundant adrenal steroid in humans. Serum levels of DHEA
and DHEA-S exhibit a characteristic change with aging, rising
during adolescence, peaking in the second decade of life and
gradual falling thereafter, whereas serum levels of other adre-
nal steroids, such as cortisol and aldosterone, do not change
with age. Since the falling levels of DHEA and DHEA-S
parallel aging-related pathophysiologies, many investigators
have been interested in the e¡ects of administration of
DHEA and DHEA-S in elderly people [1].
DHEA is a free steroid with weak androgenic activities and
DHEA-S is regarded to be an inactive conjugate that exerts its
e¡ects through the release of DHEA by the steroid sulfatase.
It has been postulated that DHEA, like other steroid hor-
mones, may have its own nuclear receptor, however, no spe-
ci¢c receptor has yet been identi¢ed and the molecular mech-
anism(s) of its action remains unknown. On the other hand,
several reports have indicated that DHEA-S per se might have
direct and speci¢c actions. For example, DHEA-S blocked
gamma-amino-butyric acid (GABA)-induced ion currents in
neurons as an allosteric antagonist of the GABAA receptor
in vitro [2], and in vivo treatment with DHEA-S induced a
peroxisome proliferating activity in mice [3].
The observation that the e¡ects of DHEA-S appear to be
mediated by a nuclear peroxisome proliferator activated re-
ceptor (PPAR) K, though indirectly [3], prompted us to inves-
tigate the in vivo e¡ects of DHEA and DHEA-S on other
nuclear receptor functions. We were particularly interested
in analyzing constitutive androstane receptor L (CARL), since
its ligands, androstanol and androstenol, are 17-deoxy-ste-
roids and are thought to have a close relationship with 17-
oxy-steroids such as DHEA and DHEA-S.
2. Materials and methods
2.1. Animals and diets
To study the e¡ect of DHEA and DHEA-S, we used C57 ksj +m/
+m mice, because they are the parental strain of db/db mice in which
the anti-diabetic action and modulation of hepatic glucose-6-phospha-
tase activity by DHEA was demonstrated [4,5]. Male C57Bl ksj +m/
+m mice were purchased from Clea Japan (Tokyo, Japan). Three mice
were placed in one cage and given food and water ad libitum through-
out the study. A total of 24 mice, aged 9 weeks, were maintained on
standard pellet food for 15 days (Oriental MF; Oriental, Tokyo,
Japan). The mice were then divided into three equal groups for the
administration of DHEA-containing, DHEA-S-containing and stan-
dard pellet food, respectively, for 15 days. DHEA or DHEA-S, ob-
tained from Sigma Chemical Co. (St. Louis, MO, USA), was mixed
with the standard powder food and pelleted by Oriental Co. Ltd.
(Tokyo, Japan) at a ¢nal concentration of 0.4% (w/w). On day 16,
mice were sacri¢ced by cervical dislocation. Liver and adipose tissues
were removed and weighed. All animal studies were performed after
obtaining the approval of the Osaka Medical College Animal Care
and Use Committee.
2.2. Histological analysis
Resected livers were ¢xed in 10% formalin and embedded in paraf-
¢n. Sections were stained with hematoxylin and eosin (HE) for light
microscopy. For electron microscopy, formalin-¢xed specimens were
re¢xed in 2% osmic acid.
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2.3. Preparation of nuclear extracts
Nuclear extracts were prepared as previously described [6]. Brie£y,
freshly excised liver specimens were homogenized in the homogenizing
bu¡er (0.35 M sucrose, 10 mM HEPES^KOH, pH 7.9, 10 mM KCl,
0.1 mM EDTA, 0.5 mM phenylmethylsulfonyl £uoride (PMSF), 14
Wg/ml aprotinin, 0.15 mM spermine, 0.5 mM spermidine). Crude nu-
clear fraction was prepared from the homogenates and extracted with
the extraction bu¡er (20 mM HEPES^KOH, pH 7.9, 0.33 M NaCl,
1.5 mM MgCl2, 10% glycerol, 14 Wg/ml aprotinin, 0.5 mM DTT, 0.5
mM PMSF). Protein concentration of nuclear extract was measured
by BCA Protein Assay Kit (Pierce, USA).
2.4. Electrophoretic mobility shift assay (EMSA)
In vitro DNA binding activities of nuclear receptors were analyzed
by EMSA using liver nuclear extracts. Nuclear extracts containing
5 Wg of protein were preincubated in the binding bu¡er (25 mM
HEPES, pH 7.9, 0.2 mM EDTA, 100 mM KCl, 3 mM MgCl2, 2 Wg
poly(dI-dC), 10% glycerol) on ice for 15 min, then, incubated with
32P-labeled double stranded oligonucleotide probe (50 000 cpm) for 60
min on ice. In antibody supershift experiments, incubation was con-
tinued for another 60 min on ice after the addition of each polyclonal
antibody (anti-CARL, anti-RXRK, anti-RAR, anti-PPARK, anti-
PPARQ and anti-PXR, Santa Cruz, CA, USA). Complexes containing
DNA probes were resolved by electrophoresis on 5% polyacrylamide
gels using 0.5UTBE bu¡er (100 V at room temperature), and ana-
lyzed by autoradiography as described [6].
2.5. Oligonucleotides
Double-stranded oligonucleotides corresponding to the vitamin D
receptor responsive element (VDRE) [7], the steroid and xenobiotic
receptor responsive element (SXRE) [8], the retinoic acid receptor
responsive element (RARE) [9], the retinoic acid receptor L2 respon-
sive element (LRARE) [10] and the promoter region of the enoyl-CoA
hydratase/3-hydroxyacyl-CoA dehydrogenase gene as the PPAR re-
sponsive element (HD-PPRE) [11] were end-labeled with the Klenow
fragment of DNA polymerase I and [K-32P]dATP for EMSA [6].
The corresponding sequences were: VDRE: 5P-AGCTTGCTCGG-
GTAGGGTTCCACGAGGTTCACTCGACTCGT-3P, SXRE: 5P-G-
ATCTTCTGAACTCAAAGGAGGTCAGGAA-3P, RARE: 5P-AG-
CTTCAGGTCACCAGGAGGTCAGAGAGCT-3P, LRARE: 5P-A-
AGGGTTCACCGAAAGTTCACTCGCATTAAGGGTTCACCGA-
AAGTTCACTCGCATA-3P, HD-PPRE: 5P-CCTCTCCTTTGACC-
TATTGAAACTATTACCTACATTTGA-3P.
2.6. Western blot analysis
Liver nuclear extracts containing 20 Wg of protein were separated by
sodium dodecyl sulfate^polyacrylamide gel electrophoresis (12% poly-
acrylamide gel) and then electroblotted onto Imobilon P (Millipore,
Bedford, MA, USA). Membranes were incubated with a polyclonal
antibody against CARL (1:750 dilution) or RXRK (1:1500 dilution)
(Santa Cruz, CA, USA) and processed with chemiluminescence detec-
tion system (Amersham-Pharmacia Biotech, UK). Chemiluminescence
signals were analyzed densitometrically using the NIH image soft-
ware.
2.7. Real-time PCR quanti¢cation of the Cyp2b10 gene expression
Treated animals were killed and livers were immediately immersed
into RNAlater (Ambion, Austin, TX, USA). Total RNA was ex-
tracted using Isogen (Nippongene, Japan) and cDNA was produced
using RT-PCR Kit (Takara, Japan). The quantitative real-time, one-
step PCR was performed using the LightCycler quick system using
SYBRGreen I kit (Roche Diagnostics GmbH, Germany) according to
the manufacturer’s instructions. The quanti¢cation data were ana-
lyzed with the LightCycler analysis software, as described previously
[12,13]. Expression levels of the Cyp2b10 mRNA were normalized by
the levels of the endogenous G3PDH mRNA. The primers for mouse
Cyp2b10 cDNA [14] were 5P-CGTGAATTCCTTGAAGGTTGGCT-
CAACGACAG and 5P-CGTGAATTCAACATTGGTTAGACCAG-
GACCATGG. The primers for mouse G3PDH cDNA as internal
control are 5P-GGGTGTGAACCACGAGAAAT and 5P-CTGCTTC-
ACCACCTTCTTGA.
2.8. Measurement of serum levels of DHEA and DHEA-S
Serum levels of DHEA and DHEA-S were measured by ELISA in
SRL Co. Ltd. (Tokyo, Japan).
3. Results
3.1. DHEA and DHEA-S induce hepatomegaly and peroxisome
proliferation
Administration of DHEA or DHEA-S increased serum
concentrations of both DHEA and DHEA-S (Table 1). These
treatments also increased liver weight and the liver to whole
body weight ratio, but not epididymal adipose tissue weight
(Table 1). Microscopic examination revealed that DHEA-S
and DHEA induced liver peroxisome proliferation (data not
shown) as described previously [15]. Increase in liver weight
and peroxisome proliferation were more prominent in DHEA-
S-treated mice than in DHEA-treated mice.
3.2. DHEA and DHEA-S enhance RARE- and
L-RARE-binding activity containing RXR but not RAR
As shown in Fig. 1, DHEA or DHEA-S treatment mark-
edly enhanced the binding activity of liver nuclear extracts to
RARE. On the other hand, there was little di¡erence in the
DNA binding activities to VDRE and SXRE among three
groups.
To further clarify the components of the RARE-bound
complex, another EMSA was performed using LRARE, an
element closely related to RARE [10,16]. Just like with
RARE, in vivo DHEA and DHEA-S treatment enhanced
the DNA binding activity to LRARE (Fig. 1). Bands were
supershifted by anti-RXRK but not by anti-RAR antibodies
(Fig. 2, lanes 3 and 9). These observations clearly indicate that
RXR but not RAR is involved in the enhanced DNA binding
activities to RARE and LRARE in DHEA- and DHEA-S-
treated mouse liver.
3.3. DHEA and DHEA-S treatment enhance the DNA binding
activity of the CARL-containing complex
Since it was reported that CARL could bind to the LRARE
in heterodimer with RXR [10,16], we investigated the involve-
ment of CARL in the enhanced DNA binding activity. The
components of the LRARE bound complexes were super-
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Fig. 1. DHEA- and DHEA-S-treatment enhanced the DNA binding
activity of liver nuclear extracts to RARE and LRARE, but neither
to VDRE nor SXRE. EMSAs were performed with liver nuclear ex-
tracts from control-treated, 0.4% (w/w) DHEA-treated and 0.4%
(w/w) DHEA-S-treated mice using 32P-labeled VDRE, SXRE, RARE
and LRARE as probes. DHEA treatment and to a much greater ex-
tent, DHEA-S treatment enhanced the DNA binding activity of liv-
er nuclear extracts to RARE and LRARE. The bands were dimin-
ished by an excess amount of unlabeled LRARE (lanes 13^15) or
RARE (data not shown).
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shifted by not only anti-RXRK but also anti-CARL (Fig. 2,
lanes 7 and 14). As Kassam and colleagues [11] have shown
that the CARL-RXR heterodimer also binds to HD-PPRE,
another EMSA was performed using HD-PPRE as a probe.
DHEA and DHEA-S treatment also enhanced the DNA bind-
ing activity to HD-PPRE (Fig. 3). And they disappeared with
an excess amount of unlabeled HD-PPRE (Fig. 3, lanes 7^9).
To examine the involvement of CARL in the enhanced DNA
binding activity by DHEA/DHEA-S, supershift assays were
performed with anti-CARL antibody (Fig. 3). As shown in
Fig. 3, anti-CARL antibody supershifted the DHEA/DHEA-
S-enhanced binding to HD-PPRE (Fig. 3, lane 6), as to
LRARE. From these observations, it was concluded that in
vivo DHEA/DHEA-S treatment enhanced the DNA binding
activity of a complex containing the RXR-CARL heterodimer
in mouse liver.
3.4. DHEA and DHEA-S increase the quantity of nuclear RXR
protein, but not of CARL protein
We next examined whether treatment with DHEA or
DHEA-S alters the quantity of RXR and CARL proteins in
mouse liver. As shown in Fig. 4A, larger amounts of RXRK
protein were present in liver nuclear extracts from DHEA-
and DHEA-S-treated mice compared with those from control
mice. Neither DHEA nor DHEA-S a¡ected the quantity of
CARL protein in mouse liver nuclear extracts (Fig. 4B).
3.5. DHEA and DHEA-S induce the expression of a target
gene of RXR-CARL
We investigated whether DHEA and DHEA-S altered the
expression of the target gene of the CARL/RXR heterodimer.
As shown in Fig. 5, both DHEA and DHEA-S induced the
expression of the mouse Cyp2b10 gene, a target gene of
CARL/RXR. There is a correlation between the expression
level of Cyp2b10 gene and serum concentration of DHEA-S
in DHEA-treated mice (Fig. 6), and an inverse correlation in
DHEA-S-treated mice. On the other hand, there is no corre-
lation between the expression level of Cyp2b10 gene and se-
rum DHEA concentration (data not shown).
4. Discussion
In the present study, we investigated the e¡ects of treatment
with DHEA and DHEA-S on the activities of nuclear hor-
mone receptors, since several lines of evidence have suggested
that actions of DHEA and DHEA-S were mediated through
nuclear hormone receptors. For example, PPARK had been
regarded as a candidate receptor for DHEA and DHEA-S
because of the absence of the peroxisome proliferative e¡ect
Table 1
Whole body weight, liver weight, epididymal fat weight, serum concentrations of DHEA and serum concentrations of DHEA-S in control,
DHEA-treated and DHEA-S-treated mice (meanRS.D.)
Whole body
weight (g)
Fat
(g)
Liver
(g)
Ratio of liver/whole
body weight (%)
DHEA
(ng/ml)
DHEA-S
(ng/ml)
Control 22.27R 1.61 0.37R 0.21 1.17R 0.11 5.26R 0.39 0.867R0.186 69.667R 0.210
0.4% DHEA 20.33R 0.55 0.30R 0.10 1.47R 0.08 7.23R 0.21 198.800R120.238 281.900R 91.599
0.4% DHEA-S 23.80R 1.48 0.34R 0.05 2.27R 0.18 9.52R 0.38 43.167R5.879 434.167R 123.935
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Fig. 2. DHEA- and DHEA-S-treatment enhanced the DNA binding
activity of the complex containing RXRK and CARL to LRARE.
EMSAs were performed with liver nuclear extracts from control-
treated (C), DHEA-treated (D) and DHEA-S-treated (S) mice.
Supershift assays with anti-RXRK, anti-RAR or anti-CARL anti-
body. The arrow indicates the band supershifted by anti-RXRK
antibody (lanes 3 and 9) and anti-CARL antibody (lanes 7 and 14)
and the arrowhead indicates the disappeared band by supershift,
showing the involvement of RXR and CARL in the LRARE^nu-
clear protein complex. No supershifted bands were observed with ei-
ther anti-RAR (lane 10) or anti-PPARK antibodies (lane 11).
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Fig. 3. The DNA binding activity to HD-PPRE is also enhanced
DHEA and DHEA-S treatment. EMSAs were performed with liver
nuclear extracts prepared from control-treated (C), DHEA-treated
(D) and DHEA-S-treated (S) mice, using 32P-labelled HD-PPRE as
probes. The arrow indicates band supershifted by anti-RXRK anti-
body (lane 3) and anti-CARL antibody (lane 6) and the arrowhead
indicates disappeared bands, showing the involvement of RXRK^
CARL in the HD-PPRE nuclear protein complex. These bands dis-
appeared by an excess amount of unlabeled HD-PPRE (lanes 7^9).
No supershifted bands were observed with anti-PPARK (lane 4) or
anti-PPARQ antibodies (lane 5).
FEBS 26810 5-12-02
A. Fujita et al./FEBS Letters 532 (2002) 373^378 375
of DHEA-S in PPARK knockout mice, although it was dem-
onstrated later that neither DHEA nor DHEA-S activated
PPARK directly [3]. We demonstrated that in vivo treatment
with DHEA and DHEA-S not only speci¢cally enhanced the
DNA binding activity of the CARL-RXR heterodimer but
also induced the expression of the CARL target gene.
The increased target DNA binding in DHEA- or DHEA-S-
treated mice could be due to the receptor activation by in-
creased ligand binding in vivo. In vivo conversion of DHEA
and DHEA-S to androstanol and androstenol, CARL ligands,
could occur and they could a¡ect CARL activity, since both
androstanol and androstenol are 17-deoxy-steroids and have a
close relationship with 17-oxy-steroids such as DHEA and
DHEA-S [17]. In fact, there are two reports suggesting the
production of androstenol from DHEA and DHEA-S in hu-
man [18,19]. Mason and Schneider reported the detection of a
musk-smelling androst-16-en-3K-ol in the urine of two female
patients with adrenal cortical neoplasm, which were supposed
to secrete excessive amounts of glucocorticoids and adrenal
androgens including DHEA and DHEA-S. This musk-smell-
ing steroid was assumed to be androstenol, 5K-androst-16-en-
3K-ol, since 5L-androst-16-en-3K-ol is odorless [20]. They pro-
posed that androstenol was a product of the adrenal cortical
neoplasm or a product of the metabolism of some precursor
produced by the neoplasm. Thus, DHEA or DHEA-S could
be converted to CARL ligands in vivo and enhance the DNA
binding activity of the CARL-RXR heterodimer.
The ¢nding that DHEA and DHEA-S treatment increased
the amount of RXR in liver nuclear extracts suggests that
increase in the amount of the CARL-RXR heterodimer is
another possible mechanism involved in the enhancement of
target DNA binding. The increase of RXR could be a result
of an increase in RXR gene transcription, a result of elonga-
tion of the half-life of RXR mRNA or protein, or a result of
an increase of nuclear localization of RXR. However, it seems
that the increase of RXR protein is not the only mechanism of
the enhanced DNA binding of the CARL-RXR heterodimer
because we could not detect the e¡ect of DHEA/DHEA-S on
DNA binding activity with various nuclear hormone respon-
sive elements targeted by heterodimers between RXR and
other heterodimer partners than CARL (Fig. 1). Other possi-
ble mechanisms include the post-translational modi¢cations of
CARL-RXR and co-factors, by DHEA or DHEA-S treat-
ment, to gain the enhanced target DNA binding ability. All
these above mentioned mechanisms are not mutually exclusive
and could work synergistically. For example, the modi¢cation
of RXR might increase its half-life and nuclear localization,
both of which could lead to the increased amount of nuclear
RXR.
We showed peroxisome proliferation and hepatomegaly by
DHEA or DHEA-S treatment, as previously reported. Inter-
estingly, HD-PPRE, which is the upstream sequence of the
peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehy-
drogenase gene, contains both PPARK-responsive and
CARL-responsive elements [11]. Because the knockout mice
study showed that both DHEA and DHEA-S could induce
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Fig. 4. DHEA and DHEA-S treatment increased nuclear RXR pro-
tein but not nuclear CARL protein. Western blot analyses were per-
formed with liver nuclear extracts from control, DHEA-treated and
DHEA-S-treated mice using anti-RXR polyclonal antibody (1:1500
dilution) (A) or anti-CARL polyclonal antibody (1:750 dilution)
(B). Arrows indicate RXR and CARL.
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Fig. 5. DHEA or DHEA-S treatment induced the expression of
mouse Cyp2b10 mRNA. The expression levels of mouse Cyp2b10
and G3PDH gene were quanti¢ed by real-time RT-PCR. The levels
of Cyp2b10 were normalized by the G3PDH mRNA levels and ex-
pressed as relative arbitrary unit. Data are meanRS.D. Open bar:
control-treated, closed bar: DHEA-treated, hatched bar: DHEA-S-
treated mice. Statistical analysis was performed by the Cochran^
Cox’s test.
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the peroxisome proliferation but could not activate PPARK
directly [3], it is a possible new physiological function of
CARL. In next step, we would examine the peroxisome pro-
liferation and the enoyl-CoA hydratase/3-hydroxyacyl-CoA
dehydrogenase gene expression in DHEA- or DHEA-S-
treated mice. Our results may suggest another mechanism of
the peroxisome proliferation induced by DHEA/DHEA-S^
CARL pathway.
DHEA and DHEA-S not only enhanced the target DNA
binding of CARL, but also modulated the expression of a
target gene of CARL in mouse liver. These results strongly
suggest that DHEA and DHEA-S a¡ect the transcriptional
activity of the CARL-RXR heterodimer in vivo. Because
our in vitro experiments suggest DHEA-S can not activate
CARL directly (A. Fujita and D. Furutama, unpublished
data), as DHEA can not [10], they would be converted to
regulators for CARL in vivo. Natural ligands of CARL, an-
drostanol and androstenol, are thought to be negative regu-
lators of CARL for its target gene transcription because of the
direct inhibitory e¡ect of these substances on the interaction
between CARL and SRC1 [10], whereas another ligand of
CARL, phenobarbital, can act as a positive regulator [21].
One of the possible regulators for CARL, which could be
converted from DHEA/DHEA-S in vivo, is estradiol. It is
known as a metabolite of DHEA [22] and to activate CARL
and induce the Cyp2b10 gene expression in mouse liver [23].
However, estradiol could elicit nuclear accumulation of CAR
in the mouse livers [23], which has not been seen in DHEA- or
DHEA-S-treated mice, suggesting that another unknown pos-
itive regulator could be produced from DHEA(-S). Androste-
nol and androstanol could be also converted from DHEA/
DHEA-S in vivo. In addition, DHEA can be converted
from DHEA-S by steroid sulfatase and DHEA-S can be con-
verted from DHEA by DHEA sulfotransferase. Thus, various
regulators, which are in vivo metabolites by preferential con-
version from DHEA or DHEA-S, could a¡ect the CARL
activity and the expression of CARL target genes positively
or negatively.
It remains unknown why in vivo e¡ects of DHEA/DHEA-
S, including the peroxisome proliferation, the enhancement of
DNA binding of CARL and the induction of its target gene,
were more prominent in DHEA-S-treated mice than in
DHEA-treated mice. Since di¡erences in these e¡ects between
DHEA and DHEA-S are only quantitative throughout our
study, the greater e¡ects of DHEA-S could be simply ex-
plained by assuming that, for example, DHEA-S is a better
substrate than DHEA for the converting enzyme, generating
CARL ligands. We speculate the preferential conversion of
DHEA-S to androstenol or androstanol, because the position
17 of DHEA-S is more easily modi¢ed than that of DHEA
because the position 3 of DHEA-S is blocked by sulfate [24].
Such in vivo preferential conversion, i.e. DHEA-S to CARL
ligands and DHEA to estradiol or other activators, could
account for the di¡erential e¡ects of DHEA and DHEA-S
on the target gene induction and DNA binding. In addition,
it could account for the discrepancy between the target DNA
binding activity and the target gene expression level in
DHEA(-S)-treated mice. Elucidation of the relationship be-
tween CARL activation and in vivo conversion of DHEA/
DHEA-S to CARL ligands is the necessary next step. We
believe that our current data about the e¡ects of DHEA
and DHEA-S on CARL and RXR provide important clues
to clarify the physiological functions of DHEA and DHEA-S.
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